Citi Global Wealth Investments Issues Mid-Year Outlook 2021: Traveling to the post-COVID world - New portfolios for a new economy
Citi Global Wealth Investments today released its Mid-Year Outlook 2021 report, Traveling to the post-COVID world: New portfolios for a new economy. Released twice yearly, Citi’s outlook explains why this recovery will be strong due to swift and deep government stimulus and vaccine effectiveness. This sets the stage for several new near-term and long-term opportunities for investors.
Citi Global Wealth Investments expects that digitization, climate change, increased US-Chinese competition and government spending policies will reshape industries. The pandemic focused attention on these issues and their economic impact will provide many companies with new growth potential. This allow portfolios to move beyond our previous approach of “exploiting mean reversion” that focused on investing in areas hardest hit by the recession and riding the recovery. Additionally, our eyes are also on the many governments that intend to make greater investment in infrastructure reshaping their own economies.
“Long before the arrival of effective vaccines, we made the case for a full recovery in the global economy. We advised clients to remain invested and to add to their equity allocations early on,” said David Bailin, Chief Investment Officer and Global Head of Investments for Citi Global Wealth. “Now, we look to exploit the trends that will reshape the world after COVID. We caution, however, that many of the best near- term investments aren’t necessarily those we envisage leading markets higher longer-term. We want client portfolios to evolve and reflect the transformational opportunities to come.”
Unprecedented monetary and fiscal easing measures, effective vaccines and tech-powered productivity improvements have helped lower the chances of another economic contraction any time soon. Therefore, Citi continues to recommend allocations toward regions and industries where valuations do not reflect a full recovery. We have recently moderated our peak equity allocation for the first time since early 2020. We’ve pivoted from some “early cycle outperformers” to global health care and dividend growth shares to try to identify more enduring returns.
As the economic recovery continues to play out, long-term bond yields are likely to trend higher. That is why we still have a large underweight in bonds. Citi has added floating bank rate loans to portfolios that can do better in such an environment.
“While much of what we highlight in Mid-Year Outlook 2021 are portfolio approaches that will benefit from a steadily improving economic recovery, we also note areas of caution,” said David Bailin. “These challenges could include COVID mutations and cybersecurity concerns. That is why we seek to preserve and grow wealth by way of a globally diversified asset allocation rather than taking highly concentrated risks.”
What has gained momentum is Citi Global Wealth Investment’s focus on “Unstoppable Trends”. The pandemic promoted digitization - how businesses and consumer alike embraced new technology to live and work; greening the world – the collapse of fossil fuel demand and energy prices during the first lockdown and what that means for the rollout of clean energy; and the rise of Asia – how strategic engagement between China and the U.S. will look in the future.
The full report, a summary version, short videos, and other materials can be accessed here.
Citi Global Wealth was formed in January 2021 to deliver Citi’s wealth solutions, products and services globally to help enable clients achieve their financial goals.
About Citi:
Citi, the leading global bank, has approximately 200 million customer accounts and does business in more than 160 countries and jurisdictions. Citi provides consumers, corporations, governments and institutions with a broad range of financial products and services, including consumer banking and credit, corporate and investment banking, securities brokerage, transaction services, and wealth management. Additional information may be found at www.citigroup.com | Twitter: @Citi | YouTube: www.youtube.com/citi | Blog: http://blog.citigroup.com | Facebook: www.facebook.com/citi | LinkedIn: www.linkedin.com/company/citi.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210603005972/en/
Contact information
North America:
Gabriel Morales
+1 718 248 7029
gabriel.morales@citi.com
EMEA:
Allister Fowler
+44 7873 73586
allister.fowler@citi.com
APAC:
Godwin Chellam
+852 2868-7682
godwin.chellam@citi.com
LATAM:
Alex Ravinet
+1 305 420 4292
alexandra.ravinet@citi.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Making Science Unveils ‘AWAKE’: The AI Venture Studio Industrialising Startup Creation and AI-First Innovative Solutions23.12.2025 20:51:00 CET | Press Release
Making Science, the global digital acceleration consultancy, today announced the launch of AWAKE Venture Studio. This "AI-first" model represents a new era in systematic innovation, designed to identify, prototype, and scale both internal proprietary solutions and independent AI-native startups with global reach. The launch of AWAKE is motivated by the significant efficiency gains of orders of magnitude that Making Science has already achieved through the internal integration of AI. By applying these methods, the firm has achieved a 2x acceleration in tech feature development reducing time in the deployment of AI Agents. This model has already proven its commercial and innovative power through the acceleration of startups like ad-machina, which has multiplied its value by 10 since joining the Making Science ecosystem. These proven benchmarks serve as the technical foundation for AWAKE’s two interconnected engines, which formalise this efficiency into a repeatable manufacturing process
FDA Clears First Extended Depth of Focus Contact Lens for Presbyopia23.12.2025 18:07:00 CET | Press Release
The Cataltheia Group and its U.S. subsidiary, Bruno Vision Care LLC, a leader in eye health innovation, today announced that the U.S. Food and Drug Administration (FDA) has cleared the first and only Daily Disposable Soft (Hydrophilic) Contact Lens for Presbyopia utilizing patented Extended Depth of Focus (EDOF) optical design technology, enabling commercial distribution in the United States. Deseyne® delivers smooth, continuous focus across near, intermediate, and distance vision, providing clear, natural vision without compromise. This performance is enabled by Cataltheia’s patented hyper-refractive central zone, engineered to precisely redirect light in a controlled manner. The result is a clear clinical advantage over the only other available contact lens option for presbyopia, multifocal lenses, which rely on multiple optical zones and often require prolonged visual and cognitive adaptation. “We are proud to offer the first contact lens solution for the world’s aging population th
Aramco Awards SLB Long-Term Contract to Support Kingdom’s Unconventional Gas Production Growth23.12.2025 14:58:00 CET | Press Release
Global technology company SLB (NYSE: SLB) has been awarded a five-year contract by Aramco to provide stimulation services for its unconventional gas fields. This award is part of a broader multi-billion contract, supporting one of the largest unconventional gas development programs globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251223074948/en/ The contract encompasses advanced stimulation, well intervention, frac automation, and digital solutions, which are important to unlocking the potential of Saudi Arabia’s unconventional gas resources. The contract encompasses advanced stimulation, well intervention, frac automation, and digital solutions, which are important to unlocking the potential of Saudi Arabia’s unconventional gas resources — a cornerstone of the Kingdom’s strategy to diversify its energy portfolio and support the global energy transition. “This agreement is an important step forward in Aramco’s effor
Tabelog, Japan's Largest (*1) Restaurant Search and Reservation Service, Launches Multilingual App for International Visitors23.12.2025 14:00:00 CET | Press Release
Tabelog (https://tabelog.com/en/), Japan's largest restaurant search and reservation service operated by Kakaku.com, Inc., launched its multilingual smartphone application (iOS/Android) for international travelers on Monday, November 17, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251221963753/en/ The Tabelog Multilingual App for International Travelers — Japan's Largest Restaurant Search and Reservation Service With approximately 100 million monthly users(*3), Tabelog is Japan's premier service widely used by Japanese locals for daily restaurant discovery. Its database is unrivaled domestically, featuring information on approximately 890,000 establishments nationwide and over 85 million reviews and photos(*4). Unlike global map services or travel sites, Tabelog is built on "authentic ratings and reviews from local Japanese users," enabling travelers to discover truly exceptional restaurants beloved by locals — not
BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference23.12.2025 12:01:00 CET | Press Release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, with a presentation at 7:30 am PST. Live webcasts of these events can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com, https://hkexir.beonemedicines.com, https://sseir.beonemedicines.com. Archived replays will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company based in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of nearly 12,000 colleagues spanning six continents, the Company is committed to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
